Persistent Asset Partners Ltd Purchases 49,508 Shares of TG Therapeutics, Inc. $TGTX

Persistent Asset Partners Ltd boosted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 137.2% in the second quarter, Holdings Channel.com reports. The firm owned 85,580 shares of the biopharmaceutical company’s stock after acquiring an additional 49,508 shares during the quarter. TG Therapeutics makes up about 2.3% of Persistent Asset Partners Ltd’s holdings, making the stock its 7th largest position. Persistent Asset Partners Ltd’s holdings in TG Therapeutics were worth $3,080,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in TGTX. Rockefeller Capital Management L.P. purchased a new position in shares of TG Therapeutics during the 2nd quarter worth approximately $420,000. SG Americas Securities LLC grew its holdings in TG Therapeutics by 190.2% during the second quarter. SG Americas Securities LLC now owns 9,289 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 6,088 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in TG Therapeutics by 1,221.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock worth $15,191,000 after acquiring an additional 390,137 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in TG Therapeutics by 10.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 32,914 shares of the biopharmaceutical company’s stock valued at $1,185,000 after acquiring an additional 3,174 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of TG Therapeutics by 6.3% during the 2nd quarter. Geode Capital Management LLC now owns 3,490,457 shares of the biopharmaceutical company’s stock worth $126,033,000 after purchasing an additional 207,890 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insider Buying and Selling

In related news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director owned 94,061 shares in the company, valued at approximately $3,032,526.64. This trade represents a 18.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 10.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a report on Thursday. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. HC Wainwright started coverage on TG Therapeutics in a report on Monday, October 6th. They set a “buy” rating and a $60.00 price objective for the company. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. raised their price target on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $50.25.

TG Therapeutics Trading Up 0.1%

Shares of TG Therapeutics stock opened at $31.00 on Friday. TG Therapeutics, Inc. has a 1 year low of $25.28 and a 1 year high of $46.48. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. The business has a 50 day moving average price of $33.90 and a 200 day moving average price of $34.31. The company has a market capitalization of $4.92 billion, a P/E ratio of 83.78 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. During the same quarter last year, the business posted $0.02 earnings per share. TG Therapeutics’s revenue was up 92.7% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.